Analyst Research

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : ValuEngine, Inc.
$49.00
Provider : Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alcobra Ltd presents positive results from phase IIb study of Metadoxine Extended Release (MDX) in adults with Predominantly Inattentive ADHD


Monday, 5 May 2014 08:00am EDT 

Alcobra Ltd:Says presentation of data from Phase IIb study of drug candidate MDX (Metadoxine Extended Release) in adults with Predominantly Inattentive ADHD (PI-ADHD). 

Company Quote

7.6
-0.18 -2.31%
4 Sep 2015